非布司他片联合依托考昔治疗痛风性关节炎的效果及对血清炎症因子的影响  

The effect of Febuxostat combined with Etoricoxib in the treatment of patients with gout arthritis and its effect on serum inflammatory factors

作　　者：赖爱云[1] 徐健[1] 陶丽[1] LAI Aiyun;XU Jian;TAO Li(Department of Rheumatology,the First Affiliated Hospital of Kunming Medical University,Yunnan Province,Kunming 650032,China)

机构地区：[1]昆明医科大学第一附属医院风湿免疫科,云南昆明650032

出　　处：《中国医药导报》2018年第9期101-104,共4页China Medical Herald

基　　金：云南省医疗卫生科技计划项目(2016NS051)

摘　　要：目的观察非布司他片联合依托考昔对痛风性关节炎患者的临床疗效及对血清炎症指标的影响。方法选择2015年10月~2016年10月就诊于昆明医科大学第一附属医院的76例痛风性关节炎患者,按照奇偶数法随机平均分为两组,各38例。对照组患者给予依托考昔片口服治疗,120 mg/次,1次/d,连续服用1周。观察组在对照组基础上加用非布司他片联合治疗,口服,40 mg/次,1次/d,连续服用1周。观察两组患者临床疗效,疼痛改善及尿酸(UA)、白细胞介素1β(IL-1β)、肿瘤坏死因子(TNF-α)、红细胞沉降率(ESR)、C反应蛋白(CRP)水平变化情况,比较两组患者不良反应发生情况。结果观察组总有效率高于对照组,差异有统计学意义(P<0.05);两组患者治疗后视觉模拟评分(VAS评分)均明显降低,观察组VAS评分低于对照组,差异有统计学意义(P<0.05);两组患者治疗后UA、IL-1β、TNF-α、ESR、CRP水平均较治疗前明显降低,观察组各因子降低水平均优于对照组,差异有统计学意义(P<0.05);两组的不良反应率比较差异无统计学意义(P>0.05)。结论非布司他片联合依托考昔在痛风性关节炎的治疗中效果显著,优于单用依托考昔,显著改善了患者临床症状及血清炎症因子水平,安全性较好,值得临床推广。Objective To observe the clinical effect of Febuxostat combined with Etoricoxib in the treatment of patients with gout arthritis and its effect on serum inflammatory factors.Methods Seventy-six patients with gout arthritis from October 2015 to October 2016 in the First Affiliated Hospital of Kunming Medical University were selected and randomly divided into control group and observation group by the odd even method,with 38 cases in each group.Patients in the control group were treated with Etoricoxib,120 mg/time,once per day,for 1 week in a row.The observation group was treated with a combination of Febuxostat on the basis of the control group,40 mg/time,once per day,for 1 week in a row.The clinical efficacy,pain relief and uric acid(UA),interleukin 1(IL-1β),tumor necrosis factor(TNF-α),erythrocyte sedimentation rate(ESR),c-reactive protein(CRP)level of the two groups were observed and the adverse reaction were compared.Results The total effective rate of observation group was higher than control group,the difference was statistically significant(P<0.05).After treatment,the visual simulation score(VAS score)of the two groups was significantly reduced,and the VAS score in the observation group was lower than that in the control group,the difference was statistically significant(P<0.05).After treatment,the level of UA,IL-1β,TNF-α,ESR and CRP level in two groups were significantly lower than before treatment,and the levels of each factor in the observation group were better than those in the control group,the differences were statistically significant(P<0.05).There was no statistically significant of adverse reaction rates between the two groups(P>0.05).Conclusion The efficacy of Febuxostat combined with Etoricoxib in the treatment of gout arthritis has significantly efficiency,it is superior to use Etoricoxib singly.The clinical symptoms and serum inflammatory factors were significantly improved,and the safety is good,which is worthy of clinical promotion.

关 键 词：非布司他片 依托考昔 痛风性关节炎 炎症因子 

分 类 号：R259[医药卫生—中西医结合]